NovaBay Pharmaceuticals Inc.

0.610000.00Vol 189 9911Y Perf -46.42%
Nov 11th, 2019 15:59
BID0.5900 ASK0.6200
Open0.6000 Previous Close0.6100
Pre-Market0.59 After-Market-
 -0.02 -3.28%  - -%
Target Price
1.10 
Analyst Rating
Strong Buy 1.00
Potential %
80.33 
Finscreener Ranking
★★ —    -
Insiders Trans % 3/6/12M
-/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-100/-100 
Growth Ranking
     31.97
Insiders Shares Cnt. % 3/6/12M
-/-100/-100 
Income Ranking
 —    -
Market Cap (M)17 
Earnings Rating
Buy
Price Range Ratio 52W %
9.97 
Earnings Date
7th Nov 2019

Today's Price Range

0.57000.6400

52W Range

0.23004.04

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
5.17%
1 Month
-6.15%
3 Months
-35.79%
6 Months
7.02%
1 Year
-46.42%
3 Years
-86.99%
5 Years
-96.70%
10 Years
-98.86%

TickerPriceChg.Chg.%
NBY0.61000.00000.00
AAPL262.202.06000.79
GOOG1 299.19-12.1800-0.93
MSFT146.110.15000.10
XOM70.34-0.4300-0.61
WFC54.05-0.0500-0.09
JNJ131.98-1.0200-0.77
FB189.61-1.2300-0.64
GE11.35-0.1700-1.48
JPM129.92-0.4600-0.35
Earnings HistoryEstimateReportedSurprise %
Q03 2019--0.02-
Q02 2019--0.14-
Q01 2019--0.24-
Q04 2018-0.14-0.0935.71
Q03 2018-0.09-0.11-22.22
Q02 2018-0.12-0.15-25.00
Q01 2018-0.07-0.14-100.00
Q04 2017-0.050.02140.00
Earnings Per EndEstimateRevision %Trend
3/2019 QR-0.18-20.00Negative
6/2019 QR-0.0650.00Positive
12/2019 FY-0.47--
12/2020 FY-0.20--
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume189 991
Shares Outstanding (K)27 902
Trades Count503
Dollar Volume109 577
Avg. Volume1 125 288
Avg. Weekly Volume692 919
Avg. Monthly Volume351 110
Avg. Quarterly Volume888 151
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
0 (0.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
RatingStrong Buy
1.00
Strong Buy
1.00
-

NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company. The company develops, manufactures, and markets anti-infective products for a multitude of uses. It is predominantly focused on commercializing prescription Avenova for the domestic eyecare market in the United States. Avenova is the only eye care product formulated with proprietary, stable and pure form of hypochlorous acid (marketed as Neutrox). NovaBay develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. It has partnerships for NeutroPhase in the United States, as well as in other markets.

CEO: Justin M. Hall

Teplephone: +1 510 899-8800

Address: 2000 Powell Street, Emeryville 94608, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

47%53%

Bearish Bullish

58%43%

News

Stocktwits